```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:49:09 ON 01 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 Jun 2004  VOL 140 ISS 23
FILE LAST UPDATED: 31 May 2004  (20040531/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d que l35
L11         3364 SEA FILE=REGISTRY NC2NC2NC2NC2NC2NC5/ESS
L12         3342 SEA FILE=REGISTRY NR>3 AND L11
L24              STR
```



```
VAR G1=OH/60
```

VAR G2=H/65
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L28 225 SEA FILE=REGISTRY SUB=L12 SSS FUL L24
L29 8 SEA FILE=HCAPLUS L28
L33 11 SEA FILE=REGISTRY (165727-74-2/BI OR 106359-64-2/BI OR 144371-85-7/BI OR 152490-93-2/BI OR 152868-85-4/BI OR 165727-69-5/BI OR 165727-70-8/BI OR 165727-73-1/BI OR 165727-82-2/BI OR 165727-83-3/BI OR 16712-64-4/BI OR 20276-55-5/BI OR 6066-82-6/BI OR 629-04-9/BI OR 138328-74-2/BI OR 141518-38-9/BI OR 141518-53-8/BI OR 152868-93-4/BI OR 152868-94-5/BI OR 165727-71-9/BI OR 165727-72-0/BI OR 165727-75-3/BI OR 165727-76-4/BI OR 165727-77-5/BI OR 165727-78-6/BI OR 165727-79-7/BI OR 165727-80-0/BI OR 165727-81-1/BI OR 165727-84-4/BI OR 165727-85-5/BI OR 165727-86-6/BI OR 165727-87-7/BI OR 165727-88-8/BI OR 165727-89-9/BI OR 165727-90-2/BI OR 166019-71-2/BI OR 166019-73-4/BI OR 166019-74-5/BI OR 167090-46-2/BI OR 167090-47-3/BI OR 167090-48-4/BI OR 167090-49-5/BI OR 167090-50-8/BI OR 167090-51-9/BI OR 167090-52-0/BI OR 167090-53-1/BI OR 167090-54-2/BI OR 167090-55-3/BI OR 167090-56-4/BI OR 167090-57-5/BI OR 167090-58-6/BI OR 167090-59-7/BI OR 167090-60-0/BI OR 167090-61-1/BI OR 167090-62-2/BI OR 167090-63-3/BI OR 167090-64-4/BI OR 167090-65-5/BI OR 167090-66-6/BI OR 167090-67-7/BI OR 167090-68-8/BI OR 167090-69-9/BI OR 167090-70-2/BI OR 167090-72-4/BI OR 167090-73-5/BI OR 167090-74-6/BI OR 168110-44-9/BI OR 168110-45-0/BI OR 168110-46-1/BI OR 168110-47-2/BI OR 168110-48-3/BI OR 1931-98-2/BI OR 298-12-4/BI OR 3275-13-6/BI OR 59748-15-1/BI OR 68-11-1/BI OR 69367-31-3/BI OR 75-79-6/BI OR 79-08-3/BI OR 79287-72-2/BI OR 883-40-9/BI OR 9037-30-3/BI) AND L28
L34 2 SEA FILE=HCAPLUS L33
L35 6 SEA FILE=HCAPLUS L29 NOT L34

=> d ibib abs l35 1-6

L35 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:930947 HCAPLUS
DOCUMENT NUMBER: 139:399787
TITLE: Pharmaceutical composition
INVENTOR(S): Ohnaka, Chika; Nakai, Mayumi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co. Ltd., Japan
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003220237	A1	20031127	US 2003-408558	20030408
PRIORITY APPLN. INFO.:			AU 2002-1883 A	20020422

Search completed by David Schreiber x22526

OTHER SOURCE(S): MARPAT 139:399787

AB A pharmaceutical composition comprising a cyclic peptide or its salt and cyclodextrins is provided. The composition further comprises a pH adjuster and/or a pH buffer, i.e., an amino acid. The peptide is having antimicrobial activity and is suitable for the treatment of infectious diseases.

L35 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:656795 HCAPLUS
DOCUMENT NUMBER: 139:197770
TITLE: Preparation of lipopeptides having antimicrobial activity
INVENTOR(S): Mizuno, Hiroaki; Matsuda, Hiroshi; Toda, Ayako; Matsuya, Takahiro; Barrett, David; Matsuda, Keiji
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068807	A2	20030821	WO 2003-JP1107	20030204
WO 2003068807	A3	20040415		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2002-441 A 20020211
OTHER SOURCE(S): MARPAT 139:197770
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to new lipopeptides I [R1 = H, acyl; R2 = carbamoyl, (protected) aminoalkyl or guanidinoalkyl, hydroxy-substituted alkylaminoalkyl; R3 = = H, OH; R4 = aminoalkyl, alkylcarbamoylalkyl, carboxyalkyl, etc.; R5 = OH or protected hydroxy] or their salts which have antimicrobial activities (especially antifungal activity) and inhibitory activity on β-1,3-glucan synthase and to a process for their synthesis. Pharmaceutical compns. containing I are used for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal. Thus, cyclic peptide II.2HCl [R = p-[4-[(4-methoxybutoxy)methyl]-1-piperidinyl]phenyl] was prepared by N-acylation of I (R1 = H) and showed MIC < 0.2 μg/mL against Candida albicans.

L35 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:716311 HCAPLUS
DOCUMENT NUMBER: 137:247927
TITLE: Preparation of cyclic peptides having antimicrobial activity
INVENTOR(S): Toda, Ayako; Mizuno, Hiroaki; Matsuya, Takahiro; Matsuda, Hiroshi; Murano, Kenji; Barrett, David; Ogino, Takashi; Matsuda, Keiji
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072621	A2	20020919	WO 2002-JP2109	20020307
WO 2002072621	A3	20030530		
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1366066	A2	20031203	EP 2002-703926	20020307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: AU 2001-3620 A 20010308
WO 2002-JP2109 W 20020307
OTHER SOURCE(S): MARPAT 137:247927
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to new cyclic peptides I (R1 = acyl; R2 = H, acyl; R3 = lower alkoxy which has one or more hydroxy or protected hydroxy groups; R4 = H, OH; R5 = H, OH, lower alkoxy, hydroxysulfonyloxy; R6 = OH, acyloxy) or their salts which have antimicrobial activities, especially antifungal activity. Pharmaceutical compns. containing I are used for prophylactic and/or therapeutic treatment of infectious diseases including infection (e.g. pneumonia) in a human being or an animal. Thus, cyclic peptide II [R = p-[(4-phenyl-1-piperidinyl)oxy]phenyl] was prepared by N-acylation of I (R1 = H) and showed MIC < 0.3 μg/mL against Candida albicans.

L35 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:521773 HCAPLUS
DOCUMENT NUMBER: 137:98997
TITLE: Stabilized pharmaceutical composition containing a cyclic polypeptide in lyophilized form
INVENTOR(S): Miyake, Kouzou; Ohtomo, Kazumi; Kasai, Akihiro
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053584	A1	20020711	WO 2001-JP11242	20011221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2000-2344 A 20001228

OTHER SOURCE(S): MARPAT 137:98997

GI



I

AB A stabilized pharmaceutical composition in lyophilized form comprises (i) a cyclic polypeptide I (R1,R2 = H, acyl; R3 = alkyl, R4 = H, OH; R5 = H, OH, alkoxy, hydroxysulfonyloxy; R6 = OH, acyloxy) or its salt, and (ii) a polysaccharide, e.g., dextran, as a stabilizer. The composition further comprises a pH adjuster and/or a pH buffer. An injection formulation is prepared by dissolving the lyophilized composition in isotonic NaCl solution; the injection can or should be used for preventing or treating infection diseases, especially fungal infections. For example, a lyophilized composition each containing 10 mg of I was prepared from I 0.2 g, dextran 40 2 g, glycine 0.3 g, and NaOH.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:618024 HCAPLUS
DOCUMENT NUMBER: 135:180954
TITLE: Synthesis of cyclic hexapeptide derivatives for use as antimicrobial or antifungal agents in humans or animals
INVENTOR(S): Toda, Ayako; Matsuya, Takahiro; Mizuno, Hiroaki; Matsuda, Hiroshi; Murano, Kenji; Barrett, David; Ogino, Takashi; Matsuda, Keiji
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060846	A1	20010823	WO 2001-JP1204	20010220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001034095	A5	20010827	AU 2001-34095	20010220
EP 1259535	A1	20021127	EP 2001-906140	20010220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008792	A	20021203	BR 2001-8792	20010220
JP 2003523349	T2	20030805	JP 2001-560230	20010220
RU 2224765	C1	20040227	RU 2002-125463	20010220
NZ 520808	A	20040326	NZ 2001-520808	20010220
US 2003083238	A1	20030501	US 2002-30161	20020130
NO 2002003697	A	20021014	NO 2002-3697	20020806

PRIORITY APPLN. INFO.:
AU 2000-5752 A 20000221
AU 2000-9552 A 20000821
AU 2000-2344 A 20001228
WO 2001-JP1204 W 20010220

OTHER SOURCE(S): MARPAT 135:180954
GI

Search completed by David Schreiber x22526



I

AB Cyclic polypeptides [(I); R, R1 (independently) = H, acyl; R2 = hydroxyalkyl; R3 = H, OH; R4 = H, OH, alkoxy, HO3SO-; R5 = OH, acyloxy], useful as antimicrobial or antifungal agents, or as β-1,3-glucan synthase inhibitors (no data), for use in prophylactic and/or therapeutic treatment of infectious diseases in humans or animals, were prepared A variety of substituted acyl R groups were prepared and coupled with the cyclopeptide. Thus, I [R = 4-[2-[4-[4-[5-methoxypentyloxy]piperidin-1-yl]phenyl]imidazo[2,1-b][1,3,4]thiadiazol-6-yl]phenylcarbonyl; R1,R3 = H; R2 = CH(CH2OH)2; R4 = HO3SO; R5 = OH (II)] was prepared in four steps from the starting protected cyclic peptide sodium salt and activated ester of substituted benzoic acid (preparation given). In in vitro tests of antimicrobial activity in mouse serum against Candida albicans FP-633, II had MIC <0.3 μg/mL.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2000:772658 HCAPLUS
DOCUMENT NUMBER:	133:335462
TITLE:	Preparation of cyclic hexapeptides having antibiotic activity
INVENTOR(S):	Tojo, Takashi; Ohki, Hidenori; Shiraishi, Nobuyuki; Matsuya, Takahiro; Matsuda, Hiroshi; Murano, Kenji; Barrett, David; Ogino, Takashi; Matsuda, Keiji; Ichihara, Masaharu; Hashimoto, Norio; Kanda, Atsushi; Ohigashi, Atsushi
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE:	PCT Int. Appl., 449 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

Search completed by David Schreiber x22526

WO 2000064927	A1	20001102	WO 2000-JP2710	20000425
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1173472	A1	20020123	EP 2000-917469	20000425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003501347	T2	20030114	JP 2000-614276	20000425

PRIORITY APPLN. INFO.: AU 1999-9997 A 19990427
WO 2000-JP2710 W 20000425

OTHER SOURCE(S): MARPAT 133:335462
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclic hexapeptides I [R1 = H, acyl; R2, R3 = H, cyano, (un)substituted alkyl, acyl, heterocyclyl, alkylidenyl; R4 = H, OH; R5 = H, OH, alkoxy, hydroxysulfonyloxy; R6 = OH, acyloxy] or their salts were prepared for use as antimicrobials, especially fungicides. Thus, cyclic peptide II [R1 = p-[5-[4'-(2-methoxyethoxy)[1,1'-biphenyl]-4-yl]thiazol-2-yl]benzoyl], prepared via N-acylation reaction, showed MIC <0.3 μg/mL for inhibition of Candida albicans.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que l34
L11 3364 SEA FILE=REGISTRY NC2NC2NC2NC2NC2NC5/ESS
L12 3342 SEA FILE=REGISTRY NR>3 AND L11
L24 STR

Search completed by David Schreiber x22526



VAR G1=OH/60
VAR G2=H/65
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L28 225 SEA FILE=REGISTRY SUB=L12 SSS FUL L24
L33 11 SEA FILE=REGISTRY (165727-74-2/BI OR 106359-64-2/BI OR 144371-85-7/BI OR 152490-93-2/BI OR 152868-85-4/BI OR 165727-69-5/BI OR 165727-70-8/BI OR 165727-73-1/BI OR 165727-82-2/BI OR 165727-83-3/BI OR 16712-64-4/BI OR 20276-55-5/BI OR 6066-82-6/BI OR 629-04-9/BI OR 138328-74-2/BI OR 141518-38-9/BI OR 141518-53-8/BI OR 152868-93-4/BI OR 152868-94-5/BI OR 165727-71-9/BI OR 165727-72-0/BI OR 165727-75-3/BI OR 165727-76-4/BI OR 165727-77-5/BI OR 165727-78-6/BI OR 165727-79-7/BI OR 165727-80-0/BI OR 165727-81-1/BI OR 165727-84-4/BI OR 165727-85-5/BI OR 165727-86-6/BI OR 165727-87-7/BI OR 165727-88-8/BI OR 165727-89-9/BI OR 165727-90-2/BI OR 166019-71-2/BI OR 166019-73-4/BI OR 166019-74-5/BI OR 167090-46-2/BI OR 167090-47-3/BI OR 167090-48-4/BI OR 167090-49-5/BI OR 167090-50-8/BI OR 167090-51-9/BI OR 167090-52-0/BI OR 167090-53-1/BI OR 167090-54-2/BI OR 167090-55-3/BI OR 167090-56-4/BI OR 167090-57-5/BI OR 167090-58-6/BI OR 167090-59-7/BI OR 167090-60-0/BI OR 167090-61-1/BI OR 167090-62

Search completed by David Schreiber x22526

-2/BI OR 167090-63-3/BI OR 167090-64-4/BI OR 167090-65-5/BI OR 167090-66-6/BI OR 167090-67-7/BI OR 167090-68-8/BI OR 167090-69-9/BI OR 167090-70-2/BI OR 167090-72-4/BI OR 167090-73-5/BI OR 167090-74-6/BI OR 168110-44-9/BI OR 168110-45-0/BI OR 168110-46-1/BI OR 168110-47-2/BI OR 168110-48-3/BI OR 1931-98-2/BI OR 298-12-4/BI OR 3275-13-6/BI OR 59748-15-1/BI OR 68-11-1/BI OR 69367-31-3/BI OR 75-79-6/BI OR 79-08-3/BI OR 79287-72-2/BI OR 883-40-9/BI OR 9037-30-3/BI) AND L28

L34 2 SEA FILE=HCAPLUS L33

=> d ibib abs hitstr l34 1-2

L34 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:763519 HCAPLUS
DOCUMENT NUMBER: 123:228903
TITLE: Preparation of cyclic peptide compounds as β-1,3-glucan synthase inhibitors and antimicrobial agents
INVENTOR(S): Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Can. Pat. Appl., 85 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2123921	AA	19941118	CA 1994-2123921	19940517
AU 9461994	A1	19941124	AU 1994-61994	19940510
AU 681119	B2	19970821		
IL 109615	A1	20001206	IL 1994-109615	19940510
EP 644199	A1	19950322	EP 1994-107406	19940512
EP 644199	B1	20000719		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 194846	E	20000815	AT 1994-107406	19940512
ES 2148254	T3	20001016	ES 1994-107406	19940512
PT 644199	T	20010131	PT 1994-107406	19940512
CN 1100104	A	19950315	CN 1994-105193	19940516
CN 1057306	B	20001011		
ZA 9403356	A	19950328	ZA 1994-3356	19940516
HU 68385	A2	19950628	HU 1994-1515	19940516
US 5569646	A	19961029	US 1994-242854	19940516
RU 2164230	C2	20010320	RU 1994-16354	19940516
JP 06340693	A2	19941213	JP 1994-126977	19940517
US 5693750	A	19971202	US 1996-675212	19960703
GR 3034366	T3	20001229	GR 2000-402052	20000908

PRIORITY APPLN. INFO.: GB 1993-10091 A 19930517
GB 1993-25269 A 19931210
US 1994-242854 A3 19940516

OTHER SOURCE(S): MARPAT 123:228903
GI

Search completed by David Schreiber x22526

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclic peptide compds. [I; R1 = H; R2 = acyl; R3 = OH, acyloxy; R4 =HO, OSO3H; R5 = H or a lower alkyl group which is optionally substituted with a HO, acyl, di(lower)alkylamino or cyclic amino group; R6 = H, OH, or acyl-lower alkylthio] and pharmaceutically acceptable salts thereof, useful as fungicides for the treatment of Pneumocystis carinii infection, are prepared Thus, 0.285 g NaBH3CN was added to a solution of 1 g I (R1 = R3 = R6 = OH, R2 = Q, R4 = NaO3SO, R5 = H) in CF3CO2H containing mol. sieves 4A and the resulting mixture was stirred at ambient temperature for 1 h to give, after chromatog. by an ion-exchange column on DOWEX 50WX4 (Na+-type) and HPLC using a C18μ Bondpak resin, column chromatog. on ODS (YMC-gel ODS-AMS-50), and lyophilization, 318 mg I (R1 = R5 = H, R2 = Q, R3 = R6 = OH, R4 = NaO3SO) and 263 mg I (R1 = R5 = R6 = H, R2 = Q, R6 = OH, R4 = NaO3SO). I (R1 = R5 = H, R2 = Q1, R3 = R6 = OH, R4 = NaO3SO) showed IC50 of 0.05 μg/mL against Candida albicans YU-1200.

IT **165727-73-1P 165727-74-2P 165727-82-2P 165727-83-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate for preparation of fungicidal cyclic peptide compds.)

RN 165727-73-1 HCAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



Search completed by David Schreiber x22526

PAGE 2-A



● Na

RN 165727-74-2 HCAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 165727-82-2 HCAPLUS
CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 Na

RN 165727-83-3 HCAPLUS
CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-

threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● Na

IT **167090-57-5P 167090-58-6P 167090-65-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic peptide compds. as β-1,3-glucan synthase inhibitors and fungicides)

RN 167090-57-5 HCAPLUS

CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-erythro-4-hydroxy-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 167090-58-6 HCAPLUS

CN Pneumocandin A0, 1-[erythro-4-hydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 167090-65-5 HCAPLUS
CN Pneumocandin A0, 1-[N2-[[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]carbonyl]-erythro-4-hydroxy-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, disodium salt (9CI) (CA INDEX NAME)

Search completed by David Schreiber x22526

PAGE 1-A



PAGE 2-A



●2 Na

IT **165727-74-2 168110-47-2 168110-48-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction in preparation of fungicidal cyclic peptide compds.)

RN 165727-74-2 HCAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

Search completed by David Schreiber x22526

PAGE 1-A



PAGE 2-A



● Na

RN 168110-47-2 HCAPLUS

CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● Na

RN 168110-48-3 HCAPLUS
CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]- (9CI) (CA INDEX NAME)



L34 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:716709 HCAPLUS
DOCUMENT NUMBER: 123:112725
TITLE: preparation of polypeptides as antimicrobials
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06192292	A2	19940712	JP 1993-248668	19930909
PRIORITY APPLN. INFO.:			GB 1992-19068	19920909

OTHER SOURCE(S): MARPAT 123:112725
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = OH, alkoxy; R2 = OH; R3 = acyl; R4, R5 = OH; R6 = OH, alkanoyloxy; (un)protected carboxyalkoxy; R7 = OH, hydroxysulfonyloxy, (un)protected carboxyalkoxy; R8 = H, (un)substituted alkyl; R1R2 or R3R4 = Q; R9, R10 = H, alkyl; with provisos] and their salts are prepared Over 20 I were prepared with data; however, no specific exptl. procedures are given for the preparation of individual compds. I [R1 = R2 = R4 = R5 = R6 = R7 = R8 = OH, R3 = 6-(octyloxy)-2-naphthoyl, R8 = H] (also prepared) had an IC50 of 0.2 μg/mL against Candida albicans.

Search completed by David Schreiber x22526

IT **165727-73-1P 165727-74-2P 165727-75-3P**
165727-76-4P 165727-82-2P 165727-83-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polypeptides as antimicrobials)

RN 165727-73-1 HCAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RN 165727-74-2 HCAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[4-(octyloxy)benzoyl]-L-

ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 165727-75-3 HCAPLUS

CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[[6-(octyloxy)-2-naphthalenyl]carbonyl]-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● Na

RN 165727-76-4 HCAPLUS
CN Pneumocandin A0, 1-[(4R,5R)-4,5-dihydroxy-N2-[[6-(octyloxy)-2-naphthalenyl]carbonyl]-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 Na

RN 165727-82-2 HCAPLUS
CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[4-hydroxy-(S)-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 Na

RN 165727-83-3 HCAPLUS
CN Pneumocandin A0, 1-[N2-[[6-(heptyloxy)-2-naphthalenyl]carbonyl]-(4R,5R)-4,5-dihydroxy-L-ornithine]-4-[4-(3,4-dihydroxyphenyl)-(S)-4-hydroxy-L-threonine]-5-[N-(carboxyhydroxymethyl)-threo-3-hydroxy-L-glutamine]-, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● Na